TY - JOUR
T1 - Telemedicine Use During the COVID-19 Pandemic by Resilient Rheumatology Providers
T2 - A National Veterans Affairs Follow-up Survey
AU - Singh, Jasvinder A.
AU - Richards, John S.
AU - Chang, Elizabeth
AU - Joseph, Amy M.
AU - Ng, Bernard
N1 - Funding Information:
JAS is supported through a Veterans Affairs (VA) Health Services Research and Development Award (IIR-13-314). This material is the result of work supported by research funds from the Division of Rheumatology at the University of Alabama at Birmingham (UAB) and the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA. The funding body did not play any role in the design, collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. 1J.A. Singh, MBBS, MPH, Medicine Service, Birmingham VA Medical Center, Birmingham, Department of Medicine at School of Medicine, and Division of Epidemiology at School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama; 2J.S. Richards, MBBS, VA Pittsburgh Healthcare System, and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; 3E. Chang, MD, MSCI, Phoenix VA Medical Center, Phoenix, Arizona; 4A.M. Joseph, MD, VA St. Louis Health Care System, and Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri; 5B. Ng, MBBS, MSc, University of Washington, Division of Rheumatology, and VA Puget Sound Health Care System, Seattle, Washington, USA. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs Inc., Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point Communications; and the National Institutes of Health and the American College of Rheumatology (ACR). JAS has received institutional research support from Zimmer Biomet Holdings, and food and beverage payments from Intuitive Surgical Inc./Philips Electronics North America. JAS owns stock options in TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., and Charlotte’s Web Holdings Inc. JAS previously owned stock options in Amarin, Viking, and Moderna; and is on the speaker’s bureau of Simply Speaking. JAS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 8 companies; and a member of the VA Rheumatology Field Advisory Committee. JAS is the editor and the director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the ACR Annual Meeting Planning Committee and Quality of Care Committees; Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and cochair of the ACR Criteria and Response Criteria subcommittee. AMJ has received research support from BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Singh, VA Medical Center, 700 19th St S, Birmingham, AL 35233, USA. Email: Jasvinder.md@gmail.com. Accepted for publication January 7, 2022.
Publisher Copyright:
© 2022 The Journal of Rheumatology.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Objective. To assess rheumatology provider experience and practices at Veterans Affairs (VA) facilities during the coronavirus disease 2019 (COVID-19) pandemic. Methods. We performed an anonymized follow-up national cross-sectional survey (November 5, 2020 to January 1, 2021) to assess provider resilience, experience, practices, views, and opinions about changes to medications and laboratory monitoring of veterans with rheumatic diseases. Results. Of the 143 eligible VA rheumatology providers, 114 (80%) responded. Compared to the original survey, fewer providers reported using telephone visits (78% vs 91%, P= 0.009), and more used clinical video telehealth (CVT; 16% vs 7%, P = 0.04) or in-person visits (76% vs 59%, P = 0.007). Most providers were somewhat or very comfortable with the quality of clinical encounters for established but not new patients for telephone, video-based VA Video Connect (VVC), and CVT. The mean 2-item Connor-Davidson Resilience Scale score was 6.85 (SD 1.06, range 0-8), significantly higher than the original April-May 2020 survey score of 6.35 (SD 1.26; P = 0.004). When adjusted for age, sex, and ethnicity, high provider resilience was associated with significantly higher odds of comfort with technology and the quality of the VVC visit for the following: (1) established patients (odds ratio [OR] 1.72, 95% CI, 0.67-4.40 and OR 4.13, 95% CI 1.49-11.44, respectively) and (2) new patients (OR 2.79, 95% CI 1.11-7.05, and OR 2.69, 95% CI 1.06-6.82, respectively). Conclusion. Reassuringly, VA rheumatology providers became increasingly comfortable with video visits during the first 10 months of the COVID-19 pandemic. High provider resilience, and its association with better quality CVTs, raise the possibility that video visits might be an acceptable substitute for in-person visits under appropriate circumstances.
AB - Objective. To assess rheumatology provider experience and practices at Veterans Affairs (VA) facilities during the coronavirus disease 2019 (COVID-19) pandemic. Methods. We performed an anonymized follow-up national cross-sectional survey (November 5, 2020 to January 1, 2021) to assess provider resilience, experience, practices, views, and opinions about changes to medications and laboratory monitoring of veterans with rheumatic diseases. Results. Of the 143 eligible VA rheumatology providers, 114 (80%) responded. Compared to the original survey, fewer providers reported using telephone visits (78% vs 91%, P= 0.009), and more used clinical video telehealth (CVT; 16% vs 7%, P = 0.04) or in-person visits (76% vs 59%, P = 0.007). Most providers were somewhat or very comfortable with the quality of clinical encounters for established but not new patients for telephone, video-based VA Video Connect (VVC), and CVT. The mean 2-item Connor-Davidson Resilience Scale score was 6.85 (SD 1.06, range 0-8), significantly higher than the original April-May 2020 survey score of 6.35 (SD 1.26; P = 0.004). When adjusted for age, sex, and ethnicity, high provider resilience was associated with significantly higher odds of comfort with technology and the quality of the VVC visit for the following: (1) established patients (odds ratio [OR] 1.72, 95% CI, 0.67-4.40 and OR 4.13, 95% CI 1.49-11.44, respectively) and (2) new patients (OR 2.79, 95% CI 1.11-7.05, and OR 2.69, 95% CI 1.06-6.82, respectively). Conclusion. Reassuringly, VA rheumatology providers became increasingly comfortable with video visits during the first 10 months of the COVID-19 pandemic. High provider resilience, and its association with better quality CVTs, raise the possibility that video visits might be an acceptable substitute for in-person visits under appropriate circumstances.
KW - COVID-19
KW - rheumatic disease management
KW - rheumatology provider
KW - telehealth
KW - telemedicine
KW - veterans
UR - http://www.scopus.com/inward/record.url?scp=85127474942&partnerID=8YFLogxK
U2 - 10.3899/jrheum.210967
DO - 10.3899/jrheum.210967
M3 - Article
C2 - 35105714
AN - SCOPUS:85127474942
SN - 0315-162X
VL - 49
SP - 424
EP - 431
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 4
ER -